Clinical lung cancer最新文献_第2页

A Phase II Study of Neoadjuvant Opnurasib KRAS G12C Inhibitor in Patients With Surgically Resectable Non-Small Cell Lung Cancer (CCTG IND.242A): A Substudy of the IND.242 Platform Master Protocol. 手术切除的非小细胞肺癌患者新辅助奥普那拉西卜 KRAS G12C 抑制剂的 II 期研究（CCTG IND.242A）：IND.242平台主协议的子研究。

IF 3.3 3区医学

Clinical lung cancer Pub Date : 2024-09-20 DOI: 10.1016/j.cllc.2024.09.003

J Spicer, N Blais, S Owen, A G Robinson, Q Chu, C Labbe, B Shieh, P Brown-Walker, J Sederias, K Jensen, A F Farago, M-S Tsao, T R Cottrell, B Kidane, S Laurie, R Juergens, P A Bradbury, W Tu, P-O Gaudreau

{"title":"A Phase II Study of Neoadjuvant Opnurasib KRAS G12C Inhibitor in Patients With Surgically Resectable Non-Small Cell Lung Cancer (CCTG IND.242A): A Substudy of the IND.242 Platform Master Protocol.","authors":"J Spicer, N Blais, S Owen, A G Robinson, Q Chu, C Labbe, B Shieh, P Brown-Walker, J Sederias, K Jensen, A F Farago, M-S Tsao, T R Cottrell, B Kidane, S Laurie, R Juergens, P A Bradbury, W Tu, P-O Gaudreau","doi":"10.1016/j.cllc.2024.09.003","DOIUrl":"https://doi.org/10.1016/j.cllc.2024.09.003","url":null,"abstract":"<p><p>Molecularly targeted agents are increasingly being studied in the treatment of early-stage non-small cell lung cancer (NSCLC) to try and improve cure. However, phase 3 data on neoadjuvant therapy have largely been conducted in a biomarker agnostic manner with inconsistent exclusion of EGFR and ALK alterations. Our objective was to develop IND.242 as a large-scale neoadjuvant platform trial to introduce novel agents into the preoperative window for molecularly-defined NSCLC patient populations. Given that KRAS G12C mutations are common in the overall NSCLC patient population, ranging from 9.4% to 13% of cases across different cohorts, and may be associated to worse prognosis, the initial IND.242A Substudy was designed to test neoadjuvant JDQ443 (opnurasib), a selective KRAS G12C inhibitor. This current trial report describes the multicenter, Canadian Cancer Trials Group (CCTG)-led IND.242 neoadjuvant phase 2 platform master protocol and its first Substudy (IND.242A) of neoadjuvant opnurasib KRAS G12C inhibitor for patients with surgically resectable NSCLC (AJCC 8th edition stage IA2 to IIIA). In IND.242A, a maximum of 27 patients will be accrued in participating Canadian sites. The primary objective is the rate of major pathological response (MPR) following neoadjuvant opnurasib. Secondary objectives include safety and tolerability of the treatment regimen, objective response rate (ORR) by RECIST 1.1 for the neoadjuvant treatment period, pathological complete response (pCR) rate, event-free survival (EFS) at 2 years, and surgical outcomes. Exploratory objectives are to explore patient related outcomes (PROs) and identify potential predictive biomarkers of response and mechanisms of resistance on tissue and peripheral blood samples.</p>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142406202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use of Oncogene Overlap by Tissue-Based Next-Generation Sequencing to Explore the Mutational Landscape and Survival Impact of HER2, KRAS and MET Copy-Number Gain in Nonsmall Cell Lung Cancer. 通过基于组织的新一代测序技术利用肿瘤基因重叠探索非小细胞肺癌中HER2、KRAS和MET拷贝数增殖的突变情况和对生存的影响。

IF 3.3 3区医学

Clinical lung cancer Pub Date : 2024-09-12 DOI: 10.1016/j.cllc.2024.09.001

Alexander S Watson, Harris B Krause, Andrew Elliott, Alex Farrell, Stephen V Liu, Patrick C Ma, Ari VanderWalde, George W Sledge, David Spetzler, Erin L Schenk, D Ross Camidge

{"title":"Use of Oncogene Overlap by Tissue-Based Next-Generation Sequencing to Explore the Mutational Landscape and Survival Impact of HER2, KRAS and MET Copy-Number Gain in Nonsmall Cell Lung Cancer.","authors":"Alexander S Watson, Harris B Krause, Andrew Elliott, Alex Farrell, Stephen V Liu, Patrick C Ma, Ari VanderWalde, George W Sledge, David Spetzler, Erin L Schenk, D Ross Camidge","doi":"10.1016/j.cllc.2024.09.001","DOIUrl":"https://doi.org/10.1016/j.cllc.2024.09.001","url":null,"abstract":"<p><strong>Background: </strong>Gene copy number gain (CNG) is a continuous variable. The relevant cutpoint for HER2, KRAS and MET CNG in non-mall cell lung cancer remains uncertain. As de novo driver oncogenes are largely mutually exclusive, oncogene overlap analysis can be used to explore CNG thresholds.</p><p><strong>Patient and methods: </strong>We retrospectively analysed NGS of DNA/RNA in 13,702 NSCLC adenocarcinoma samples. Alternate and same-gene driver oncogene co-occurrence with HER2, KRAS and MET CNG was examined. Overall survival (OS) from time of biopsy collection was correlated with CNG and pathogenic mutations in driver oncogenes (Driver+).</p><p><strong>Results: </strong>The frequency of Driver+ tumors decreased with increasing CNG. Setting CNG thresholds by oncogene overlap and dataset size (CNA ≥ 6 for HER2, KRAS and ≥ 4 for MET), tumors considered relevantly amplified (Amp) for MET, HER2 and KRAS were significantly less likely to be Driver+ (P < .001). When Driver+ did overlap with Amp status, same-gene alterations (mutation and CNG) were significantly enriched for all 3 genes (HER2, KRAS and MET), while BRAF and EGFR mutations were more common in MET-Amp than in HER2- or KRAS-Amp tumors. A negative OS association with Amp status was independent of Driver+ status for HER2 and MET, however not KRAS.</p><p><strong>Conclusion: </strong>Tissue NGS-based HER2, KRAS and MET CNG thresholds set by oncogene overlap identified potentially clinically relevant \"Amp\" subgroups with altered genetic profiles and decreased survival. Prospective research into targeted therapy benefit in these groups is encouraged.</p>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Smoking and the Risk of Second Primary Lung Cancer Among Breast Cancer Survivors from the Population-Based UK Biobank Study. 基于人群的英国生物库研究中乳腺癌幸存者的吸烟与第二原发性肺癌风险。

IF 3.3 3区医学

Clinical lung cancer Pub Date : 2024-09-06 DOI: 10.1016/j.cllc.2024.08.017

Anna Graber-Naidich, Eunji Choi, Julie T Wu, Timothy J Ellis-Caleo, Joel Neal, Heather A Wakelee, Allison W Kurian, Summer S Han

{"title":"Smoking and the Risk of Second Primary Lung Cancer Among Breast Cancer Survivors from the Population-Based UK Biobank Study.","authors":"Anna Graber-Naidich, Eunji Choi, Julie T Wu, Timothy J Ellis-Caleo, Joel Neal, Heather A Wakelee, Allison W Kurian, Summer S Han","doi":"10.1016/j.cllc.2024.08.017","DOIUrl":"https://doi.org/10.1016/j.cllc.2024.08.017","url":null,"abstract":"<p><strong>Objective: </strong>Long-term breast cancer (BC) survivors are known to develop second malignancies, with second primary lung cancer (SPLC) one common type. Smoking was identified as a main risk factor for SPLC among BC survivors. These findings were limited to the U.S. and focused on smoking status, not incorporating cumulative smoking exposures (eg, pack-years). We examine SPLC incidence and evaluate the associations between SPLC risk and cumulative cigarette smoking exposures and other potential factors among BC survivors in a prospective European cohort.</p><p><strong>Methods: </strong>Of 502,505 participants enrolled in the UK Biobank in 2006 to 2010, we identified 8429 patients diagnosed with BC between 2006 and 2016 and followed for second malignancies through 2016. Smoking information was collected at enrollment, and treatment data were collected using electronic health records. Multivariable cause-specific Cox regression (CSC) evaluated the association between each factor and SPLC risk.</p><p><strong>Results: </strong>Of 8429 BC patients, 40 (0.47%) developed SPLC over 45,376 person-years. The 10-year cumulative SPLC incidence was 0.48% (95% CI = 0.33%-0.62%). The CSC analysis confirmed the association between SPLC and ever-smoking status (adjusted hazard-ratio (aHR) = 3.46 (P < .001). The analysis showed a 24% increment in SPLC risk per 10 smoking pack-years among BC survivors (aHR = 1.24 per-10 pack-years, P = .01). The associations between SPLC and other variables remained statistically insignificant. We applied the USPSTF lung cancer screening eligibility criteria and found that 80% of the 40 BC survivors who developed SPLC would have been ineligible for lung cancer screening.</p><p><strong>Conclusion: </strong>In a large, European cohort, cumulative smoking exposure is significantly associated with SPLC risk among BC survivors.</p>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Brief Report: Targeted Therapies and Pancreatitis in Patients With Advanced Nonsmall Cell Lung Cancer. 简要报告：晚期非小细胞肺癌患者的靶向治疗和胰腺炎。

IF 3.3 3区医学

Clinical lung cancer Pub Date : 2024-09-03 DOI: 10.1016/j.cllc.2024.08.016

May-Lucie Meyer, Louis Gros, Natalie Décosterd, Marco Tagliamento, Arianna Marinello, David Planchard, David Combarel, Fabrice Barlesi, Jordi Remon, Benjamin Besse, Mihaela Aldea

引用次数: 0

A Phase I Open-Label Study of Cediranib Plus Etoposide and Cisplatin as First-Line Therapy for Patients With Extensive-Stage Small-Cell Lung Cancer or Metastatic Neuroendocrine Non–Small-Cell Lung Cancer 塞地拉尼联合依托泊苷和顺铂作为广泛期小细胞肺癌或转移性神经内分泌非小细胞肺癌患者一线疗法的 I 期开放标签研究

IF 3.3 3区医学

Clinical lung cancer Pub Date : 2024-09-01 DOI: 10.1016/j.cllc.2024.08.015

Kyle F. Concannon , Bonnie S. Glisson , Robert C. Doebele , Chao Huang , Marcelo Marotti , D. Ross Camidge , John V. Heymach

{"title":"A Phase I Open-Label Study of Cediranib Plus Etoposide and Cisplatin as First-Line Therapy for Patients With Extensive-Stage Small-Cell Lung Cancer or Metastatic Neuroendocrine Non–Small-Cell Lung Cancer","authors":"Kyle F. Concannon , Bonnie S. Glisson , Robert C. Doebele , Chao Huang , Marcelo Marotti , D. Ross Camidge , John V. Heymach","doi":"10.1016/j.cllc.2024.08.015","DOIUrl":"10.1016/j.cllc.2024.08.015","url":null,"abstract":"<div><h3>Introduction</h3><div>Small cell lung cancer (SCLC) is known to express high levels of the proangiogenic factor vascular endothelial growth factor (VEGF). We assessed the safety and tolerability of cediranib, an oral inhibitor of VEGF receptor tyrosine kinases, in combination with etoposide and cisplatin as first-line therapy for extensive-stage (ES) SCLC or metastatic lung neuroendocrine cancer (NEC).</div></div><div><h3>Methods</h3><div>Patients received up to six 21-day cycles of etoposide (100 mg/m<sup>2</sup>, days 1-3) and cisplatin (80 mg/m<sup>2</sup>, day 1) with once-daily cediranib until disease progression or unacceptable toxicity. Cediranib dosing started at 30 mg with de-escalation cohorts planned based on cycle 1 dose-limiting toxicities (DLTs). An expansion cohort of 12 patients was enrolled at the recommended phase II dose.</div></div><div><h3>Results</h3><div>Twenty-two patients (18 with ES SCLC, 4 with NEC) received treatment. Only 4 patients were enrolled at the 30 mg cediranib dose before other studies established 20 mg/day as the recommended dose with chemotherapy. Among the 18 patients enrolled at the 20-mg dose, common adverse events included nausea/vomiting, neutropenia, and diarrhea; 8 patients (44%) had grade 1 or 2 hypertension, and 2 (11%) had grade 3 hemoptysis. For all 18 patients, the objective response rate and median progression-free survival duration were 67% and 7.9 months. Plasma levels of VEGF were significantly higher, and those of soluble VEGFR2 were significantly lower, on day 22 than at baseline but were not correlated with tumor shrinkage.</div></div><div><h3>Conclusions</h3><div>Cediranib (20 mg) plus etoposide and cisplatin is well tolerated and has promising clinical activity.</div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142267783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to Editor: Commentary on “Influence of Tumor Cavitation on Assessing the Clinical Benefit of Anti-PD1 or PD-L1 Inhibitors in Advanced Lung Squamous Cell Carcinoma” 回复编辑：关于 "肿瘤空洞化对评估晚期肺鳞状细胞癌中抗PD1或PD-L1抑制剂临床疗效的影响 "的评论

IF 3.6 3区医学

Clinical lung cancer Pub Date : 2024-08-31 DOI: 10.1016/j.cllc.2024.08.013

Qin Chen, Xinyue Wang, Richeng Jiang

引用次数: 0

Identification and Treatment of Lung Cancer Oncogenic Drivers in a Diverse Safety Net Setting 在多元化安全网环境中识别和治疗肺癌致癌因素

IF 3.6 3区医学

Clinical lung cancer Pub Date : 2024-08-31 DOI: 10.1016/j.cllc.2024.08.014

Kalyani Narra, Bassam Ghabach, Vivek Athipatla, James-Michael Blackwell, Kari J. Teigen, Jolonda C. Bullock, Anna Diaz, David E. Gerber, Mitchell S. von Itzstein

{"title":"Identification and Treatment of Lung Cancer Oncogenic Drivers in a Diverse Safety Net Setting","authors":"Kalyani Narra, Bassam Ghabach, Vivek Athipatla, James-Michael Blackwell, Kari J. Teigen, Jolonda C. Bullock, Anna Diaz, David E. Gerber, Mitchell S. von Itzstein","doi":"10.1016/j.cllc.2024.08.014","DOIUrl":"https://doi.org/10.1016/j.cllc.2024.08.014","url":null,"abstract":"Advances in the testing and treatment of patients with nonsmall cell lung cancer (NSCLC) harboring oncogenic drivers have improved outcomes. Little is known about testing and treatment patterns in the diverse patient populations. We conducted a retrospective study in a diverse cohort of patients treated in the John Peter Smith safety net healthcare system. We determined patterns of blood- and tissue-based testing and treatment of patients with and alterations. Cox proportional-hazards regression models were used to assess the impact of and testing. A total of 220 patients were included, 97 (44%) were non-Hispanic White, 72 (33%) were Black, 28 (13%) were Hispanic, and 23(10%) were Asian. and testing increased over time from 55% and 52%, respectively, in 2017 to 87% and 82%, respectively, in 2021. Frequency of alterations were highest in Asian patients (45%) and comparable among other groups (6-13%). Frequency of alterations were highest in Hispanic (13%), and Asian (11%) patients, and were 2% for both Black and non-Hispanic White patients. In a multivariate model, lack of testing was associated with worse survival (aHR 1.6; = .003) and testing positive for (aHR 0.43; = .01) or (aHR 0.28; = .04) was associated with improved survival. Race and ethnicity were not associated with survival differences. As molecular testing for oncogenic mutations in NSCLC increases, druggable alterations such as and can be identified in all race-ethnicity groups and are associated with improved outcomes.","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142267784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding the Social Risk Factors That Avert Equitable Lung Cancer Care 了解阻碍公平肺癌治疗的社会风险因素

IF 3.6 3区医学

Clinical lung cancer Pub Date : 2024-08-31 DOI: 10.1016/j.cllc.2024.08.011

Christopher M. Kapp, Chelsi Green, Jeffrey Thiboutot, Jeremy Kim, Mary M. Pasquinelli, Benjamin Aronson, A. Christine Argento

{"title":"Understanding the Social Risk Factors That Avert Equitable Lung Cancer Care","authors":"Christopher M. Kapp, Chelsi Green, Jeffrey Thiboutot, Jeremy Kim, Mary M. Pasquinelli, Benjamin Aronson, A. Christine Argento","doi":"10.1016/j.cllc.2024.08.011","DOIUrl":"https://doi.org/10.1016/j.cllc.2024.08.011","url":null,"abstract":"Lung cancer remains the leading cause of cancer death in the United States. There is an association between certain social determinants of health (SDOH) and adverse cancer outcomes. These include Black race and low-income, which are associated with poorer adherence to lung cancer screening and presentation at a later stage of disease. We conducted a retrospective review of all patients with a diagnosis of lung cancer at a single urban, academic center from 2015 to 2021. Demographic data including race and clinical data including time taken to progress through various checkpoints (ie, concerning CT scan to diagnosis, diagnosis to treatment) were collected. Income data was approximated based on population medians at patient's home address zip code. A total of 550 patients were included in the final analysis. The study population was 57.4% Black and 61.2% of patients presenting with a household income of $40,000 US Dollars or lower based on approximated median household income. The time from CT scan to first treatment for the entire cohort was 121.3 days with no statistically significant variance by race. However, among patients presenting at stage IV, 72.7% were black and 76.0% resided in a zip code with a median income < $40,000. This study demonstrated no significant delays in progressing through checkpoints of lung cancer diagnosis and treatment on the basis of race or income approximation. Black patients and patients in low-income households were diagnosed with lung cancer at a more advanced stage. Efforts to close the gap in lung cancer disparities should be focused on targeting screening and early identification toward social groups that may be at highest risk of late presentation. Institutional focus on patient navigation through these stages should be paramount. There were no delays in progression to lung cancer diagnostic and therapeutic milestones based on race or income approximation.","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142267785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter to the Editor in Response to “Adherence to Annual Lung Cancer Screening in a Centralized Academic Program” 致编辑的信，回应 "中央学术项目中坚持年度肺癌筛查的情况"

IF 3.6 3区医学

Clinical lung cancer Pub Date : 2024-08-30 DOI: 10.1016/j.cllc.2024.08.009

Julie Wu, Theodore Thomas, Hannah F. Tavalire, Frances Vecchio, Tassos C. Kyriakides, Kristina Crothers, Michael J. Kelley, Drew Moghanaki, Scott Shofer, Fred Hendler, Lawrence Feldman

引用次数: 0

Stage-Specific Guideline Concordant Treatment Impacts on Survival in Nonsmall Cell Lung Cancer: A Novel Quality Indicator 非小细胞肺癌分期指南一致性治疗对生存期的影响：一种新的质量指标

IF 3.6 3区医学

Clinical lung cancer Pub Date : 2024-08-24 DOI: 10.1016/j.cllc.2024.08.012

Sanuki Tissera, Baki Billah, Margaret Brand, Md Nazmul Karim, Phillip Antippa, Robert Blum, Michelle Caldecott, Matthew Conron, Wasek Faisal, Susan Harden, Inger Olesen, Phil Parente, Gary Richardson, Evangeline Samuel, Katharine See, Craig Underhill, Gavin Wright, John Zalcberg, Rob G. Stirling

{"title":"Stage-Specific Guideline Concordant Treatment Impacts on Survival in Nonsmall Cell Lung Cancer: A Novel Quality Indicator","authors":"Sanuki Tissera, Baki Billah, Margaret Brand, Md Nazmul Karim, Phillip Antippa, Robert Blum, Michelle Caldecott, Matthew Conron, Wasek Faisal, Susan Harden, Inger Olesen, Phil Parente, Gary Richardson, Evangeline Samuel, Katharine See, Craig Underhill, Gavin Wright, John Zalcberg, Rob G. Stirling","doi":"10.1016/j.cllc.2024.08.012","DOIUrl":"https://doi.org/10.1016/j.cllc.2024.08.012","url":null,"abstract":"Lung cancer in Australia contributes 9% of all new cancer diagnoses and is the leading cause of cancer death and burden. Clinical practice guidelines provide evidence-based treatment recommendations for best practice management. We aimed to determine the extent of delivery of guideline-concordant treatment (GCT) and to identify modifiable variables influencing receipt of GCT and survival. Data was sourced from the Victorian Lung Cancer Registry (VLCR) in Victoria, Australia. Descriptive statistics were used to summarize patient and disease characteristics according to treatment type: GCT versus non-GCT versus no/declined treatment. Statistical analyses included multiple logistic regression, multiple COX regression and Kaplan-Meier survival estimates. 52% of patients were treated with GCT, 32.8% non-GCT and 15.2% declined or received no treatment. GCT treated patients were younger, never smoked, had no comorbidities, had better performance status, had early stage cancer, were discussed at a multidisciplinary meeting or had treatment at a higher volume hospital. Overall, patients that received GCT had a 24% lower risk of mortality compared to patients that received non-GCT. Modifiable variables impacting likelihood of receiving GCT included age, smoking status and treating hospital characteristics. Several modifiable variables were identified with positive impacts on survival including increased treatment of the elderly, smoking cessation, delivery of GCT, and treatment in higher volume hospitals. The measurement and reporting of delivery of GCT has positive impacts on survival and therefore merits consideration as an evidence-based quality indicator in the reporting of lung cancer quality and safety outcomes.","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142267788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0